Loading...
 
Mediterr J Rheumatol 2020;31(Supp 1):145-51
Treating to Target in Clinical Practice: The Results of a Questionnaire Completed by Greek Rheumatologists
Authors Information
1. AbbVie Pharmaceuticals S.A., Athens, Greece
2. Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany
References
  1. Smolen J S, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276-89.
  2. Tucker LJ, Ye W, Coates LC. Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target? Curr Rheumatol Rep 2018;20(11):71.
  3. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017;Jul 1;390(10089):73-84.
  4. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
  5. Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis 2018;77:3-17.
  6. Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, et al. The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis.  Health Technol Assess 2017;21(71):1-258.
  7. Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. Ann Rheum Dis 2016;75(8):1479-85.
  8. Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, et al. Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. J Rheumatol 2018;45;153-7.
  9. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care Res (Hoboken) 2019 Jan;71(1):2-29.
  10. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019 Oct;71(10):1599-13.
  11. http://ere.gr/assets/files/protokola/Final_ThPS_RA_2018.pdf
  12. http://ere.gr/assets/files/protokola/Final_ThPS_AxSpA_2018.pdf
  13. http://ere.gr/assets/files/protokola/Final_ThPS_PsA_2018.pdf
  14. Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, et al. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum 2014,43:447-57.
  15.  Boubouchairopoulou N, Flouri I, Drosos AA, Boki K, Settas L, Zisopoulos D, et al. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status. Clin Exp Rheumatol 2016;34:999-1005.
  16. Thomas K, Lazarini A, Kaltsonoudis E, Drosos AA, Papalopoulos I, Sidiropoulos P, et al. Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients. Mediterr J Rheumatol 2018;29(1):27-37.
  17. Flouri ID, Markatseli TE, Boki KA, Papadopoulos I, Skopouli FN, Voulgari PV, et al. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence. J Rheumatol 2018 Jun;45(6):785-94.
  18. Sfikakis PP, Bournia VK, Sidiropoulos P, Boumpas DT, Drosos AA, Kitas GD, et al. Biologic treatment for rheumatic disease: real-world big data analysis from the Greek country-wide prescription database. Clin Exp Rheumatol 2017 Jul-Aug;35(4):579-85.
  19. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011 Mar;70(3):404-13.